Myriad Genetics (MYGN) said Wednesday it expects Q4 adjusted earnings of $0.03 to $0.04 per diluted share.
Analysts surveyed by FactSet expect $0.03.
Revenue for the quarter ended Dec. 31 is expected to be in the range of $209 million to $211 million, up by about 6% to 7% from a year earlier.
Analysts polled by FactSet expect $212.9 million.
The company said it now expects 2024 adjusted EPS of $0.14 to $0.15, versus its prior guidance for $0.12 to $0.14, while revenue is now expected to be between $836 million and $838 million, compared with its guidance for $837 million to $843 million. Analysts polled by FactSet expect adjusted EPS of $0.13 on revenue of $840 million.
For 2025, the company said it expects adjusted EPS of $0.07 to $0.11 on revenue of $840 million to $860 million. Analysts surveyed by FactSet expect adjusted EPS of $0.15 on revenue of $879.5 million.
Myriad Genetics said it intends to release its actual Q4 and full-year 2024 results in February.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.